RT期刊文章SR电子T1没有证据表明复发患者的疾病活动女士用干扰素治疗Beta-1a SC tiw与干扰素Beta-1a IM qw乔在《神经学研究(P7.220)摩根富林明证据神经病学FD Lippincott Williams &威尔金斯SP P7.220 VO 84 14补充A1 Patricia Coyle A1 Juanzhi方A1阿里哈桑A1 Choon Cha A1费尔南多Dangond 首页A1安东尼红色A1马克弗里德曼年2015 UL //www.ez-admanager.com/content/84/14_Supplement/P7.220.abstract AB目的:比较干扰素的疗效Beta-1a (IFNβ-1a) 44µg给予皮下注射(SC) 3 x /周(tiw)与干扰素β-1a 30µg给肌内(IM) 1 x /周(qw)实现临床活动免费(CAF)和任何疾病活动的证据(NEDA)状态的研究证据。背景:在证据的研究中,患者复发多发性硬化症(RMS)被随机分配接受干扰素β-1a SC tiw (n = 339)或干扰素β-1a IM qw (n = 338)。设计/方法:在这篇文章的分析,分析端点是CAF(没有复发或12周证实残疾恶化[蠅增加1点扩大残疾状态量表得分])在24和48周,NEDA钆增强病变(CAF没有或新/扩大T2病灶)在24周,和修改NEDA (mNEDA;CAF没有新的/扩大T2病灶)在24和48周。额外进行分析将研究与实现NEDA状态相关的因素在治疗的前12周或12周后治疗。结果:更多的患者接受干扰素β-1a SC tiw,与干扰素β-1a IM qw, CAF状态在24周(72 vs 58 [percnt] [percnt];p < 0.001)和48周(56 [percnt] vs 46 (percnt);p = 0.01)。类似的结果支持干扰素β-1a SC被NEDA状态在24周(61年[percnt] vs 42 (percnt);p < 0.001)和mNEDA状态在24周(66 [percnt]和[percnt]; p<0.001) and Week 48 (44[percnt] vs 32[percnt]; p=0.003). CONCLUSIONS: Significantly more patients with RMS receiving IFN β-1a SC tiw than those receiving IFN β-1a IM qw achieved CAF and NEDA status. Study Supported by: EMD Serono, Inc., Rockland, MA, USA (a subsidiary of Merck KGaA, Darmstadt, Germany) and Pfizer Inc, New York, NY, USA.Disclosure: Dr. Coyle has received personal compensation for activities with AbbVie, Accordant, Acorda, Bayer, Biogen, EMD Serono, Inc., Genentech, Genzyme, Mylan, Novartis, and Teva as a consultant. Dr. Fang has received personal compensation for activities with EMD Serono as an employee. Dr. Hassan has received personal compensation for activities with EMD Serono as an employee. Dr. Cha has received personal compensation for activities with EMD Serono as an employee. Dr. Dangond has received personal compensation for activities with EMD Serono, Inc. an employee. Dr. Reder received personal compensation from Acorda Therapeutics, Inc., Bayer Pharmaceuticals Corporation, Biogen Idec, EMD Serono, Genzyme Corporation, Novartis, Pfizer Inc., Questcor, Sanofi-Aventis Pharmaceuticals, and Teva Neuroscience as a consultan Dr. Freedman has received personal compensation for activities with Bayer Healthcare, Biogen Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis, and Teva Canada Innovation.Thursday, April 23 2015, 2:00 pm-6:30 pm